Bal Pharma Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2025 and recommend a dividend of Rs.1.20 per equity share of Rs.10 each.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Limited has filed its audited financial results for the financial year ended March 31, 2025 with the exchange. Along with the results, the company has recommended a dividend of Rs.1.20 per equity share on each share with a face value of Rs.10. This works out to a 12% dividend payout on the face value of the stock. The headline does not provide detailed financial figures such as revenue, profit or margins from the results.
The dividend announcement signals that the company generated sufficient profits to reward shareholders for FY25, which is generally positive for retail investors. Without detailed numbers in the headline, investors should review the full audited results for revenue and profit trends before drawing conclusions on business performance.